Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

• Philippe Moreau,
• Halyna Pylypenko,
• Sebastian Grosicki,
• Ievgenii Karamanesht,
• Xavier Leleu,
• Grigoriy Rekhtman,
• Zvenyslava Masliak,
• Pawel Robak,
• Dixie-Lee Esseltine,
• Huaibao Feng,
• William Deraedt,
• Helgi van de Velde,
• Bertrand Arnulf

Affiliations

Philippe Moreau

University Hospital, Nantes, France

Halyna Pylypenko

Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine

Sebastian Grosicki

Medical University of Silesia, Katowice, Poland

Ievgenii Karamanesht

Kiev BMT Center, Kiev, Ukraine

Xavier Leleu

Hopital Huriez, CHRU, Lille, France

Grigoriy Rekhtman

Khmelnitskiy Regional Hospital, Khmelnitskiy, Ukraine

Zvenyslava Masliak

SI Institute of Blood Pathology and Transfusion Medicine UAMS, Lviv, Ukraine

Pawel Robak

Medical University of Lodz, Lodz, Poland

Dixie-Lee Esseltine

Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA

Huaibao Feng

Janssen Research & Development, LLC, Raritan, NJ, USA

William Deraedt

Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium

Helgi van de Velde

Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium

Bertrand Arnulf

Immuno-hématologie Department, Hôpital Saint-Louis, Paris, France